Risk factors associated with premature myocardial infarction: a systematic review protocol

Dugani, Sagar; Ayala, Ana Patricia; Reka, Roger; Hydoub, Yousif M; McCafferty, Shannon N; Murad, M. Hassan; Alsheikh‐Ali, Alawi A.; Mora, Samia

doi:10.1136/bmjopen-2018-023647

Cited by 17 publications

(15 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two researchers independently extracted the data, and any discrepancy was resolved by discussion. The quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS) independently by two researchers [19].…”

Section: Data Extraction and Quality Assessmentmentioning

confidence: 99%

The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis

Zhao

Li²,

Wang³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Background and Purpose: Pervious studies have demonstrated that the loss of EGFR T790M after Osimertinib treatment may be the cause of Osimertinib resistance. Here, we conducted a meta-analysis to evaluate the association between the persistence of EGFR T790M and the clinical benefits of Osimertinib in non-small cell lung cancer (NSCLC) patients with baseline EGFR T790M mutation. Experimental design and Methods: PUBMED, EMBASE, and Cochrane databases were searched for eligible studies that provided the survival outcomes including overall survival (OS), progression-free survival (PFS) or time to discontinuation (TTD) data for each patient treated with Osimertinib with the status of the T790M mutation tested after Osimertinib resistance. The hazard ratios (HRs) and their 95% confidence intervals (CI) were calculated for each study. Results: In total, eight eligible studies were included in the analysis, among which six studies provided the data on PFS, and the other two studies provided the TTD data. Overall, 312 patients (151 patients with the persistence of T790M) were identified. The persistence of T790M was associated with longer PFS (HR, 0.40; 95% CI, 0.19-0.84; P=0.01) and TTD (HR, 0.54; 95% CI, 0.39-0.76; P=0.0004). Furthermore, overall analysis the survival outcomes including PFS and TTD subgroups also showed preferable clinical benefits for patients with the T790M persistence (HR, 0.57; 95%CI, 0.45-0.73; P<0.00001). Conclusions: Our findings confirm the persistence of T790M is associated with the clinical benefits of Osimertinib in NSCLC patients with baseline EGFR T790M mutation treated with Osimertinib.

show abstract

Section: Data Extraction and Quality Assessmentmentioning

confidence: 99%

The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis

Zhao

Li²,

Wang³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

show abstract

“…The study protocol (PROSPERO: CRD420 18076862) has been described. 24 This study is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines (Supplemental Table 1, available online at http://www.mcpiqojournal.org). 25,26…”

Section: Methodsmentioning

confidence: 99%

Risk Factors for Premature Myocardial Infarction: A Systematic Review and Meta-analysis of 77 Studies

Dugani

Hydoub

Ayala

et al. 2021

Mayo Clinic Proceedings: Innovations, Quality & Outcomes

Self Cite

View full text Add to dashboard Cite

Objective: To evaluate the magnitude of the association between risk factors and premature myocardial infarction (MI) (men aged 18-55 years; women aged 18-65 years). Patients and Methods: We searched MEDLINE and other databases from inception through April 30, 2020, as well as bibliography of articles selected for data extraction. We selected observational studies reporting the magnitude of the association of at least 1 risk factor (demographic characteristics, lifestyle factors, clinical risk factors, or biomarkers) with premature MI and a control group. Pooled risk estimates (random effects) from all studies unadjusted and adjusted for risk factors were reported as summary odds ratios (ORs) with 95% CIs. Results: From 35,320 articles of 12.7 million participants, we extracted data on 19 risk factors from 77 studies across 58 countries. Men had a higher risk of premature MI (OR, 2.39; 95% CI, 1.71 to 3.35) than did women. Family history of cardiac disease was associated with a higher risk of premature MI (OR, 2.67; 95% CI, 2.29 to 3.27). Major modifiable risk factors associated with higher risk were current smoking (OR, 4.34; 95% CI, 3.68 to 5.12 vs no/former), diabetes mellitus (OR, 3.54; 95% CI, 2.69 to 4.65), dyslipidemia (OR, 2.94; 95% CI, 1.76 to 4.91), and hypertension (OR, 2.85; 95% CI, 2.48 to 3.27). Higher body mass index carried higher risk (OR, 1.46; 95% CI, 1.24 to 1.71 for !25 kg/m 2 vs <25 kg/ m 2 ). Biomarkers associated with 2-to 3-fold higher risk were total cholesterol levels greater than 200 mg/ dL, triglyceride levels higher than 150 mg/dL, and high-density lipoprotein cholesterol levels less than 60 mg/dL (to convert to mmol/L, multiply by 0.0259). Conclusion: Major risk factors for premature MI are mostly amenable to patient, population, and policy level interventions. Mild elevations in body mass index and triglyceride levels were associated with higher risk, which has implications for the growing worldwide epidemic of cardiometabolic diseases.

show abstract

“…An LCA model was built using 11 known and proposed risk factors for CHD as binary variables: cigarette smoking, obesity, diabetes, family history of CHD, alcohol consumption, opium addiction, hypertension, PVD, HLP, history of stroke, and MI. The included risk factors were added to the statistical model based on premature systematic review studies ( 24 , 25 ). The LCA analyses were conducted using the “poLCA” package in R 3.4.2.…”

Section: Methodsmentioning

confidence: 99%

Clusters of the Risk Markers and the Pattern of Premature Coronary Heart Disease: An Application of the Latent Class Analysis

Jahangiry

Farhangi

Najafi

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Background: Coronary heart disease (CHD) is the major cause of mortality in the world with a significant impact on the younger population. The aim of this study was to identify prematurity among patients with coronary artery bypass graft surgery (CABG) based on the clustering of CHD risk factors.Methods: Patients were recruited from an existing cohort of candidates for CABG surgery named Tehran Heart Center Coronary Outcome Measurement (THC-COM). A latent class analysis (LCA) model was formed using 11 potential risk factors as binary variables: cigarette smoking, obesity, diabetes, family history of CHD, alcohol use, opium addiction, hypertension, history of stroke, history of myocardial infarction (MI), peripheral vascular disease (PVD), and hyperlipidemia (HLP). We analyzed our data to figure out how the patients are going to be clustered based on their risk factors.Results: For 566 patients who were studied, the mean age (SD) and BMI of patients were 59.1 (8.9) and 27.3 (4.1), respectively. The LCA model fit with two latent classes was statistically significant (G2 = 824.87, df = 21, p < 0.0001). The mean (SD) age of patients for Class I and Class II was 55.66 (8.55) and 60.87 (8.66), respectively. Class I (premature) was characterized by a high probability of smoking, alcohol consumption, opium addiction, and a history of MI (P < 0.05), and class II by a high probability of obesity, diabetes, and hypertension.Conclusion: Latent class analysis calculated two groups of severe CHD with distinct risk markers. The younger group, which is characterized by smoking, addiction, and the history of MI, can be regarded as representative of premature CHD.

show abstract

Risk factors associated with premature myocardial infarction: a systematic review protocol

Cited by 17 publications

References 29 publications

The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis

The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis

Risk Factors for Premature Myocardial Infarction: A Systematic Review and Meta-analysis of 77 Studies

Clusters of the Risk Markers and the Pattern of Premature Coronary Heart Disease: An Application of the Latent Class Analysis

Contact Info

Product

Resources

About